TYMLOS provided significant increases in BMD1
Results reported in ITT population, which included patients randomized in the efficacy study; mean percentage change in BMD was last observation carried forward (LOCF).1
Secondary endpoint2; BMD captured with dual-energy absorptiometry (DXA) scans.3
BMD across demographics1
TYMLOS demonstrated consistent BMD increases for a wide range of postmenopausal women, regardless of1:
View continued efficacyresults with TYMLOS followed by alendronate
References: 1. TYMLOS™ [prescribing information]. Waltham, MA: Radius Health, Inc; 2017. 2. Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316(7):722-733. [Erratum: JAMA. 2017;317(4):442.] 3. A randomized, double-blind, placebo-controlled, comparative phase 3 multicenter study to evaluate the safety and efficacy of BA058 for injection for prevention of fracture in ambulatory postmenopausal women with severe osteoporosis and at risk of fracture [supplement 2]. Waltham, MA: Radius Health, Inc; 2015. http://jamanetwork.com/data/Journals/JAMA/935644/JOI160092supp2_prod.pdf. Accessed June 14, 2017.